Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept | Zendy

Mahdy Ranjbar | Zendy; Max Brinkmann | Zendy; Dorinja Zapf | Zendy; Yoko Miura | Zendy; Martin Rudolf | Zendy; Salvatore Grisanti | Zendy

Open Access

Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept

Author(s) -

Mahdy Ranjbar,

Max Brinkmann,

Dorinja Zapf,

Yoko Miura,

Martin Rudolf,

Salvatore Grisanti

Publication year - 2016

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000443030

Subject(s) - oxidative stress , aflibercept , bevacizumab , receptor , pharmacology , chemistry , cancer research , medicine , microbiology and biotechnology , biology , biochemistry , chemotherapy

VEGF-A is induced by oxidative stress, and functions as a survival factor for various cell types, including retinal pigment epithelial (RPE) cells. Anti-vascular endothelial growth factor (VEGF) drugs like aflibercept and bevacizumab have shown to be most effective in treating neovascular age-related macular degeneration (AMD), however uptake of the drugs might lead to interference with cell physiology. Herein, we evaluated the significance of the Fc receptor (FcR) within this context and moreover explored the impact of VEGF inhibition under normal conditions as well as under oxidative stress, in terms of potential adverse effects.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research